Syremis Therapeutics

Syremis Therapeutics is a biotechnology company focused on the development of next-generation gene therapies for rare and orphan neurological diseases. The company was established by G2 Bio Companies, an investment vehicle founded by Dr. James Wilson and the late Dr. Tachi Yamada in collaboration with Temasek. Syremis utilizes advanced adeno-associated virus (AAV) vector technologies discovered at the University of Pennsylvania's Gene Therapy Program. Its lead programs target high-unmet-need indications including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). By optimizing vector design and delivery, Syremis aims to overcome the limitations of existing genetic medicines. The company operates as a private entity based in Philadelphia, Pennsylvania.